Madrigal Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Madrigal Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-06-30 | 2010-03-31 | 2009-09-30 | 2007-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product revenue | 212,802,000 | 137,250,000 | 103,320,000 | 62,175,000 | 14,638,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of sales | 9,065,000 | 4,513,000 | 3,445,000 | 2,152,000 | 636,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| gross profit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| yoy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| qoq | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gross margin % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 54,081,000 | 44,172,000 | 25,648,000 | 68,742,000 | 71,091,000 | 71,237,000 | 70,640,000 | 70,951,000 | 68,605,000 | 62,154,000 | 70,742,000 | 68,271,000 | 58,499,000 | 47,929,000 | 52,889,000 | 54,873,000 | 51,632,000 | 45,770,000 | 53,429,000 | 53,292,000 | 44,688,000 | 33,400,000 | 24,910,000 | 19,447,000 | 15,594,000 | 12,373,000 | 6,211,000 | 5,109,000 | 5,198,000 | 6,682,000 | 6,816,000 | 4,380,000 | 7,804,921 | 3,407,000 | 14,413,000 | 16,377,000 | 16,182,000 | 16,208,000 | 18,761,000 | 17,583,000 | 17,623,000 | 17,876,000 | 16,380,000 | 11,743,000 | 11,252,000 | 12,066,000 | 10,751,000 | 10,417,000 | 9,436,000 | 9,688,000 | 10,195,000 | 9,084,000 | 13,613,000 | |
| selling, general and administrative | 196,858,000 | 167,876,000 | 141,223,000 | 107,585,000 | 105,448,000 | 80,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 260,004,000 | 216,561,000 | 170,316,000 | 178,479,000 | 177,175,000 | 152,037,000 | 117,176,000 | 98,534,000 | 86,450,000 | 78,336,000 | 85,299,000 | 80,412,000 | 70,273,000 | 57,587,000 | 64,601,000 | 63,160,000 | 61,742,000 | 52,979,000 | 59,555,000 | 58,786,000 | 50,327,000 | 38,005,000 | 29,954,000 | 24,195,000 | 22,704,000 | 18,119,000 | 11,333,000 | 7,826,000 | 7,069,000 | 8,637,000 | 8,439,000 | 6,075,000 | 14,090,518 | 3,489,000 | 6,447,000 | 17,394,000 | 19,504,000 | 20,332,000 | 19,449,000 | 21,701,000 | 22,907,000 | 21,794,000 | 22,063,000 | 20,258,000 | 14,539,000 | 14,134,000 | 14,712,000 | 13,882,000 | 13,363,000 | 12,109,000 | 12,404,000 | 13,281,000 | 12,233,000 | 17,466,000 |
| income from operations | -47,202,000 | -79,311,000 | -66,996,000 | -116,304,000 | -162,537,000 | -152,037,000 | -117,176,000 | -98,534,000 | -86,450,000 | -78,336,000 | -85,299,000 | -80,412,000 | -70,273,000 | -57,587,000 | -64,601,000 | -63,160,000 | -61,742,000 | -52,979,000 | -59,555,000 | -58,786,000 | -50,327,000 | -38,005,000 | -29,954,000 | -24,195,000 | -22,704,000 | -8,637,000 | 118,172,000 | |||||||||||||||||||||||||||
| yoy | -70.96% | -47.83% | -42.82% | 18.03% | 88.01% | 94.08% | 37.37% | 22.54% | 23.02% | 36.03% | 32.04% | 27.31% | 13.82% | 8.70% | 8.47% | 7.44% | 22.68% | 39.40% | 98.82% | 142.97% | 121.67% | |||||||||||||||||||||||||||||||||
| qoq | -40.48% | 18.38% | -42.40% | -28.44% | 6.91% | 29.75% | 18.92% | 13.98% | 10.36% | -8.16% | 6.08% | 14.43% | 22.03% | -10.86% | 2.28% | 2.30% | 16.54% | -11.04% | 1.31% | 16.81% | 32.42% | 26.88% | 23.80% | 6.57% | ||||||||||||||||||||||||||||||
| operating margin % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income | 8,227,000 | 9,370,000 | 11,079,000 | 13,019,000 | 14,222,000 | 8,334,000 | 8,953,000 | 3,298,000 | 3,551,000 | 3,776,000 | 1,076,000 | 717,000 | 323,000 | 69,000 | 52,000 | 60,000 | 91,000 | 160,000 | 432,000 | 823,000 | 1,204,000 | 1,870,000 | 2,214,000 | 2,766,000 | 3,005,000 | 3,039,000 | 2,821,000 | 1,166,000 | 705,000 | 174,000 | 92,000 | 76,000 | 41,778 | 19,000 | 17,000 | |||||||||||||||||||
| interest expense | -3,264,000 | -3,297,000 | -3,499,000 | -3,679,000 | -3,656,000 | -3,838,000 | -3,971,000 | -3,504,000 | -2,901,000 | -2,336,000 | -1,682,000 | -1,502,000 | -780,000 | 435,000 | ||||||||||||||||||||||||||||||||||||||||
| other income | -42,000 | 273,000 | 100,000 | 200,000 | 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| net income | -42,281,000 | -73,238,000 | -59,416,000 | -106,964,000 | -151,971,000 | -147,541,000 | -112,194,000 | -98,740,000 | -85,800,000 | -76,896,000 | -85,905,000 | -81,197,000 | -70,730,000 | -57,518,000 | -64,549,000 | -63,100,000 | -61,651,000 | -52,546,000 | -59,123,000 | -57,963,000 | -49,023,000 | -36,135,000 | -27,740,000 | -21,429,000 | -19,699,000 | -15,080,000 | -8,512,000 | -6,460,000 | -6,364,000 | -8,363,000 | -8,347,000 | -5,999,000 | -14,048,740 | -3,379,000 | -6,524,000 | -17,628,000 | -19,800,000 | -20,707,000 | -19,966,000 | -22,286,000 | -23,557,000 | -22,515,000 | -22,787,000 | -20,728,000 | -14,996,000 | -14,620,000 | -15,051,000 | -12,734,000 | -12,502,000 | -11,401,000 | -9,074,000 | -9,308,000 | 118,119,000 | |
| yoy | -72.18% | -50.36% | -47.04% | 8.33% | 77.12% | 91.87% | 30.60% | 21.61% | 21.31% | 33.69% | 33.08% | 28.68% | 14.73% | 9.46% | 9.18% | 8.86% | 25.76% | 45.42% | 113.13% | 170.49% | 148.86% | 139.62% | 225.89% | 231.72% | 209.54% | 80.32% | 1.98% | 7.68% | -54.70% | 147.50% | 27.94% | -65.97% | -29.05% | -83.68% | -67.32% | -20.90% | -15.95% | -8.03% | -12.38% | 7.52% | 57.09% | 54.00% | 51.40% | 62.78% | 19.95% | 28.23% | 65.87% | 36.81% | -110.58% | |||||
| qoq | -42.27% | 23.26% | -44.45% | -29.62% | 3.00% | 31.51% | 13.63% | 15.08% | 11.58% | -10.49% | 5.80% | 14.80% | 22.97% | -10.89% | 2.30% | 2.35% | 17.33% | -11.12% | 2.00% | 18.24% | 35.67% | 30.26% | 29.45% | 8.78% | 30.63% | 77.16% | 31.76% | 1.51% | -23.90% | 0.19% | 39.14% | -57.30% | 315.77% | -48.21% | -62.99% | -10.97% | -4.38% | 3.71% | -10.41% | -5.40% | 4.63% | -1.19% | 9.93% | 38.22% | 2.57% | -2.86% | 18.20% | 1.86% | 9.66% | 25.64% | -2.51% | -107.88% | ||
| net income margin % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per common share | -1,900 | -3,320 | -2,590 | -4,920 | -7,100 | -7,380 | -5,720 | -5,340 | -4,690 | -4,230 | -4,980 | -4,750 | -4,140 | -3,360 | -3,790 | -3,790 | -3,720 | -3,320 | -3,820 | -3,750 | -3,180 | -2,340 | -1,800 | -1,390 | -1,280 | -980 | -560 | -450 | -450 | -680 | -690 | -500 | -1.34 | -20 | -50 | -130 | -150 | -190 | -190 | -240 | -280 | -330 | -330 | -300 | -250 | -250 | -270 | -300 | -300 | -270 | -220 | -240 | ||
| basic and diluted weighted-average number of common shares outstanding | 22,207,017,000 | 22,091,314,000 | 21,272,962,000 | 21,745,929,000 | 21,402,646,000 | 20,001,569,000 | 18,687,774,000 | 18,476,414,000 | 18,310,952,000 | 18,187,924,000 | 17,137,201,000 | 17,103,395,000 | 17,103,395,000 | 17,103,395,000 | 16,535,188,000 | 16,639,776,000 | 16,571,322,000 | 15,840,401,000 | 15,446,638,000 | 15,448,425,000 | 15,433,348,000 | 15,429,154,000 | 15,394,659,000 | 15,415,096,000 | 15,368,986,000 | 15,364,465,000 | 15,307,872,000 | 14,383,720,000 | 14,127,868,000 | 12,378,622,000 | 12,039,005,000 | 11,955,739,000 | 10,462,182 | 137,397,015,000 | 137,362,260,000 | 135,971,551,000 | 132,295,909,000 | 108,376,264,000 | 105,774,949,000 | 94,046,278,000 | 85,438,127,000 | 69,047,161,000 | 69,034,823,000 | 68,991,371,000 | 60,661,720,000 | 57,650,412,000 | 56,366,992,000 | 42,211,858,000 | 42,166,739,000 | 42,008,818,000 | 40,342,671,000 | 39,451,592,000 | ||
| total revenues | 147,000 | 1,664,000 | 1,354,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 46,536,000 | 27,583,000 | 17,845,000 | 16,182,000 | 14,557,000 | 12,141,000 | 11,774,000 | 9,658,000 | 11,712,000 | 8,287,000 | 10,110,000 | 7,209,000 | 6,126,000 | 5,494,000 | 5,639,000 | 4,605,000 | 5,044,000 | 4,748,000 | 7,110,000 | 5,746,000 | 5,122,000 | 2,717,000 | 1,871,000 | 1,955,000 | 1,623,000 | 1,695,000 | 6,285,597 | 3,592,000 | 3,040,000 | 2,981,000 | 3,127,000 | 4,150,000 | 3,241,000 | 2,940,000 | 5,324,000 | 4,171,000 | 4,187,000 | 3,878,000 | 2,796,000 | 2,882,000 | 2,646,000 | 3,131,000 | 2,946,000 | 2,673,000 | 2,716,000 | 3,086,000 | 3,149,000 | 3,853,000 | ||||||
| gain on disposal of property and equipment | 91,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| grant revenues | 147,000 | 521,000 | 211,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| collaboration revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| license and milestone revenue | 1,143,000 | 1,143,000 | 1,143,000 | 1,143,000 | 1,143,000 | 117,171,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| total collaboration revenues | 1,143,000 | 1,143,000 | 1,143,000 | 3,360,000 | 4,023,000 | 130,405,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| license and milestone revenues | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost sharing reimbursements | 2,217,000 | 2,880,000 | 13,234,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| restructuring | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 3,490 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 3,480 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 33,882,760,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 33,904,842,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| research grant revenue | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| in-process research and development | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other compensation expense | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investment income | 725,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock beneficial conversion charge | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock dividends | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -16,741,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted weighted-average common shares outstanding | 33,390,082,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income attributable to common stockholders per share | -0.5 |
We provide you with 20 years income statements for Madrigal Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Madrigal Pharmaceuticals stock. Explore the full financial landscape of Madrigal Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Madrigal Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.